The company is developing a new class of personalized diagnostics based on nuclear magnetic resonance (NMR) technology. LipoScience’s proprietary NMR LipoProfile® test, its first marketed product, measures the number of low density lipoprotein particles(LDL-P) in blood to personalize management of risk for heart disease. The company recently received FDA clearance for Vantera®, an automated clinical analyzer that simplifies and automates. The company’s automated clinical analyzer, Vantera®, was cleared by the FDA in 2012.
LipoScience raised $45 million in its initial public offering in January 2013.
© 2020 Pappas Capital, LLC. ALL RIGHTS RESERVED.